ATE280179T1 - Prolaktin freisetzendes peptid und verwendung zur behandlung von schmerzen - Google Patents

Prolaktin freisetzendes peptid und verwendung zur behandlung von schmerzen

Info

Publication number
ATE280179T1
ATE280179T1 AT00951554T AT00951554T ATE280179T1 AT E280179 T1 ATE280179 T1 AT E280179T1 AT 00951554 T AT00951554 T AT 00951554T AT 00951554 T AT00951554 T AT 00951554T AT E280179 T1 ATE280179 T1 AT E280179T1
Authority
AT
Austria
Prior art keywords
treating pain
releasing peptide
prolactin releasing
prrp
blood pressure
Prior art date
Application number
AT00951554T
Other languages
English (en)
Inventor
Pertti Aarre Juhani Panula
Antti Pertovaara
Eija Kalso
Esa Korpi
Original Assignee
Juvantia Pharma Ltd Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Juvantia Pharma Ltd Oy filed Critical Juvantia Pharma Ltd Oy
Application granted granted Critical
Publication of ATE280179T1 publication Critical patent/ATE280179T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2842—Pain, e.g. neuropathic pain, psychogenic pain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/321—Arterial hypertension

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
AT00951554T 1999-08-03 2000-08-03 Prolaktin freisetzendes peptid und verwendung zur behandlung von schmerzen ATE280179T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36575699A 1999-08-03 1999-08-03
US53156700A 2000-03-20 2000-03-20
PCT/FI2000/000664 WO2001009182A1 (en) 1999-08-03 2000-08-03 Prolactin-releasing peptide and method for regulating autonomic functions and treating pain

Publications (1)

Publication Number Publication Date
ATE280179T1 true ATE280179T1 (de) 2004-11-15

Family

ID=27003067

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00951554T ATE280179T1 (de) 1999-08-03 2000-08-03 Prolaktin freisetzendes peptid und verwendung zur behandlung von schmerzen

Country Status (8)

Country Link
EP (1) EP1198477B1 (de)
JP (1) JP2003508025A (de)
AT (1) ATE280179T1 (de)
CA (1) CA2380573A1 (de)
DE (1) DE60015135T2 (de)
ES (1) ES2230132T3 (de)
PT (1) PT1198477E (de)
WO (1) WO2001009182A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1415301A (en) * 1999-11-18 2001-05-30 Takeda Chemical Industries Ltd. Use of peptide
US6884596B2 (en) 2000-04-28 2005-04-26 The Regents Of The University Of California Screening and therapeutic methods for promoting wakefulness and sleep
GB0024510D0 (en) * 2000-10-06 2000-11-22 Astrazeneca Ab Methods
AU2003221502A1 (en) * 2002-03-26 2003-10-08 Bayer Aktiengesellschaft Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 10 (gpr10)
RU2010114049A (ru) * 2007-09-11 2011-10-20 Мондобайотек Лабораториз Аг (Li) Cgrp в качестве терапевтического средства
JP2022539720A (ja) * 2019-07-09 2022-09-13 ラテラル、アイピー、プロプライエタリー、リミテッド ペプチド及びその使用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1208497A (en) * 1995-12-28 1997-07-28 Takeda Chemical Industries Ltd. Ligand polypeptides for the g-protein-coupled receptor protein, their production and use
AU3733199A (en) * 1998-05-21 1999-12-06 Takeda Chemical Industries Ltd. Antibodies and utilization thereof
JP2000191696A (ja) * 1998-12-25 2000-07-11 Takeda Chem Ind Ltd ペプチドの用途

Also Published As

Publication number Publication date
CA2380573A1 (en) 2001-02-08
EP1198477B1 (de) 2004-10-20
ES2230132T3 (es) 2005-05-01
PT1198477E (pt) 2005-02-28
WO2001009182A1 (en) 2001-02-08
JP2003508025A (ja) 2003-03-04
EP1198477A1 (de) 2002-04-24
DE60015135T2 (de) 2006-02-09
DE60015135D1 (de) 2004-11-25

Similar Documents

Publication Publication Date Title
HUP9700368A2 (hu) II-típusú diabetes mellitus kezelése amilin agonistákkal
ATE144420T1 (de) Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen
DE69925024D1 (de) Verwendung von eph-rezeptor-antagonisten und agonisten zur behandlung von vaskulären krankheiten
ATE459369T1 (de) Verfahren zur behandlung von entzündungen
ATE279181T1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
ATA260087A (de) Kombination von angiotensin-converting-enzyme- hemmern mit calciumantagonisten sowie ein erzeugnis, das diese enthält, zur anwendung bei der behandlung des bluthochdrucks
DE69616375D1 (de) Nicht-allosterische GABA A Agonisten zur Behandlung von Schlafstörungen
IL206829A (en) Use of an antibody-containing homologue to prepare leukocyte-induced rise in bronchoalveolar fluid-related specimen
DE69822919D1 (de) Spezifische Antikörper zur Verwendung in der Herstellung pharmazeutischer Zusammensetzungen nützlich für die Vorbeugung oder Behandlung von Gastritis, Magen- und Zwölffingerdarmgeschwüren
DE69929464D1 (de) Zyklische polyamine zur behandlung der thrombozytopenie
DE69332713D1 (de) Verwendung von Histamine-2 Agonisten zur Behandlung sexueller Funktionsstörungen
ATE545658T1 (de) Verfahren zur behandlung von synovialsarkom
DE69711078D1 (de) Topische verwendung von kappa-opioidrezeptoragonisten zur behandlung von augenschmerz
ATE210447T1 (de) Verwendung von cck-b rezeptor antagonisten zur behandlung von schlafstörungen
EE05497B1 (et) Polüpeptiid, lahustuv CRAM-1 polüpeptiid, polünukleotiid ja antikeha
ATE302025T1 (de) Vorrichtungen zur behandlung und diagnose des restless leg syndroms
DE60015135D1 (de) Prolaktin freisetzendes peptid und verwendung zur behandlung von schmerzen
ATE214925T1 (de) Neue medizinische verwendung
ATE201598T1 (de) Verwendung von moxonidin zur behandlung neuropathischer schmerzen
DE3872872D1 (de) 5-ht3-rezeptor-antagonisten zur behandlung von husten und bronchokonstriktion.
ATE222101T1 (de) Verwendung von selegilin oder desmethylselegilin zur behandlung von wunden, verbrennungen und hautschäden
DK0876158T3 (da) Ny medicinsk anvendelse af en ACE-inhibitor til behandling af mavesurhedssymptomer
KR960000921A (ko) 칼시토닌 유도체 및 그 용도
ATE242641T1 (de) Behandlung von stressinduzierten hautkrankheiten unter verwendung von corticoliberin (crh)- antagonisten und inhibitoren der hautmastzell- degranulation
DE60118769D1 (de) Verwendung von langem pentraxin ptx3 zur behanlung von durch geänderte aktivität des fgf-2 wachstumsfaktors hervorgerufene krankheiten

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1198477

Country of ref document: EP

REN Ceased due to non-payment of the annual fee